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Abstract 
Glucose regulation is compromised in diabetic patients and hence diabetes is characterized by 
accumulation of glucose in blood. As a standard practice diabetic patients usually self-administer 
subcutaneous insulin injections daily, which are usually associated with pain, tissue necrosis, 
microbial contamination and nerve damage to local areas. Glucose-responsive implantable 
devices have provided a hope for a brighter future of diabetes management. However, one of the 
limitations of such devices is their refill requirement, which often requires surgical procedures 
leading to lower patient compliance. To overcome this limitation led to the idea of reusing 
insulin after it has been in the body circulation system and later becomes residues. To make this 
idea work, the first step proposed in this thesis is to tag insulin with magnetic nanoparticles and 
then to use a magnetic guidance system to bring it back the residue insulin to the implanted 
device before it can go to the clearance sites. Obviously, the precondition for the foregoing idea 
to work is to make sure that insulin‘s conformation is not affected by the attachment with 
magnetic nanoparticles. This thesis was designed to study this precondition. The hypothesis is 
that the insulin‘s conformation will not be affected by the attachment with the magnetic 
nanoparticles. Two specific objectives are: (1) assessment of the feasibility of potential capturing 
techniques and analysis of the attachment of insulin onto the magnetic nanoparticles to confirm 
the attachment; (2) measurement of the insulin‘s conformation before and after it is attached with 
the magnetic nanoparticles. The spectroscopy techniques, including Fourier transform infrared, 
circular dichroism, absorbance and fluorescence spectroscopy, were used to conduct data 
collection and analysis. All four of these spectroscopies provide important information 
concerning the research objectives of this thesis. The results from the fluorescence and 
absorbance spectroscopy confirm the attachment of insulin onto the magnetic nanoparticles, 
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hence the achievement of Objective 1. The results from the CD and FTIR spectroscopy show that 
insulin‘s conformation is unchanged before and after its attachment onto magnetic nanoparticles, 
hence the achievement of Objective 2. The general conclusion of the study is that the insulin‘s 
conformation will not be affected by the attachment of it with magnetic nanoparticles.  
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Chapter 1: Introduction 
1.1 Background 
The world is rapidly changing due to the climatic changes of the universe, which have resulted in 
increased hormonal instabilities among the human race. These changes are enhancing the level of 
uncertain diseases along with aggravating the diseases which are already curable in our medical 
and scientific realms. It has become a dire need to develop advanced treatments and medical 
propositions which will allow us to overcome the effects of these overwhelming changes of the 
environment on humans. Deducing clinically relevant strategies and promoting a healthy lifestyle 
will provide us with hope to lead a secure life. Diabetes was once considered to be a disease that 
could be managed easily by adapting our food intake, leading an active lifestyle and taking the 
required medicine. However, currently diabetes along with obesity has turned into an epidemic 
in the world and especially in the North American communities.   
Diabetes is a chronic condition which affects the body‘s ability to properly use the energy found 
in food, usually in the form of glucose. Under normal circumstances, body breaks down the 
sugars in the food into glucose which then fuels the cells in the body. However, in order to do 
this, cells require a special hormone called insulin which helps them to take in glucose and use it 
for energy. Diabetes is a disorder of glucose regulation characterized by the improper 
accumulation of glucose in the blood. This happens because either our body doesn‘t make 
enough insulin or it does produce it but cannot use it. This then leads to the improper 
accumulation of glucose in the blood. High blood glucose levels can damage the blood vessels in 
different parts of the body including kidneys, heart, eyes and even the nervous system. 
Therefore, if left untreated diabetes can lead to heart disease, stroke, problems with eyesight and 
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nerve damage (http://www.diabetes.ca/diabetes-and-you/complications., accessed February 5, 
2018). There are two types of diabetes, Type I (insulin-dependent) and Type II (insulin-
independent). Although there is no cure available for both types of diabetes, gastric bypass 
surgery, lifestyle alteration and medicinal treatment can result in remission. Type I diabetes is 
usually treated with regular injections of insulin along with controlling blood pressure, 
cholesterol levels, physical activity and dietary modifications. Type II diabetes on the other hand 
can be managed with regular use of medication along with exercise, healthy food choices, 
controlling blood pressure and cholesterol levels (Nichols, 2017). 
In both conditions the body transfers itself into a chronic condition which affects the body‘s 
ability to regulate glucose levels within the blood. The resulting loss of homeostatic mechanisms 
leads to fluctuating levels of glucose in the body: either it can go towards a very high scale, 
which is referred to as Hyperglycemia, or towards the very low end of the scale, which is 
referred to as Hypoglycemia.  
1.2 Motivation  
This thesis concerned Type I diabetes, so insulin administration is crucial. Currently, self-
administration of insulin multiple times a day via syringes or pens based on an estimated need of 
individual patients is used alongside frequent monitoring with finger-prick testing. This type of 
insulin therapy is painful and requires strict self-discipline by the patient, leading to poor 
compliance. In addition, it can result in periods of hypo- or hyperglycemia with variability in 
caloric count, meal schedules, metabolism, and exercise ultimately hindering quality of life (De 
Grauw et al., 2001; Bradley et al., 2002; Yamada et al., 2007). This method of insulin 
administration is considered to be an open-loop system; it requires an external stimulus, patient 
3 
 
intervention in this case, and fails to mimic physiological conditions, in which the pancreas 
swiftly releases insulin in response to a rise in blood glucose. Other methods of insulin delivery, 
such as oral, intranasal, and transdermal have been studied. But, these therapies were also in an 
open-loop fashion and had limitations regarding bioavailability and clinical efficacy (Lowman et 
al., 1999; Hinchcliffe et al., 1999; Ma et al., 2006; Chen et al., 2011; Fonte et al., 2013).  
The focus, currently, is on methods that involve non-invasive insulin administration which also 
provides long term release and involves closed-loop based delivery. Closed-loop insulin therapy 
is a promising avenue of research, because it has the potential to avoid hypo- or hyperglycemic 
periods, increase compliance, and improve the quality of life in comparison with other therapies 
by eliminating the need of patient intervention and simulating insulin release by the pancreas 
(Farmer et al., 2008). Implantable insulin delivery devices with glucose responsive methods have 
gained a lot of attention. A lot of notable work has been done on these devices, which shows 
promise with further investigation. They have the potential of freeing the patients of having to 
monitor their glucose levels continuously. These devices are still under development, and one 
common problem that was seen in literature regarding these devices had to do with the insulin 
refill. In most cases, it requires surgical methods, and this causes a low compliance rate among 
the patients, along with complications that might arise after such a surgery. Reduction of the 
number of times of insulin refilling is the problem studied by this thesis.  
1.2.1 The Big Picture 
Our group proposed an idea to address this problem. If the patients could use the insulin stored in 
the implantable devices for multiple cycles it would increase the availability of insulin and would 
subsequently decrease the number of times of insulin refilling. Figure 1-1 presents an overview 
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of this idea. If insulin can be tagged with something like a magnetic nanoparticle or an antibody, 
it might be possible to pull that insulin back to the implantable device after it has performed its 
function so that it can be released once again when needed.  
 
Figure 1-1: The Big Picture 
1.3 Research Question 
There are two possible options that could be looked at in achieving this goal. The first option is 
the use of Immunoprecipitation along with an internal or external switch. Specific antibodies 
could be used to isolate the insulin in vivo to protect it from degradation by insulin degrading 
enzyme (IDE). Although this approach avoids the problems that arise by simply blocking IDE to 
increase half-life of insulin in the body, this method has drawbacks of its own, which will be 
presented in detail in literature review in the next chapter. The second approach involves using 
insulin that is tagged with magnetic nanoparticles. These nanoparticles may then allow insulin to 
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be pulled back to the device once the insulin dissociates from the insulin receptor. Based on the 
literature pertinent to the management of diabetes, the capabilities of nanoparticles, and contexts 
of this thesis study, the second approach was seen to be more viable. Further explanation will be 
provided in literature analysis in the next chapter. 
Based on the above discussion, the following specific research question to this thesis was 
formulated as: Can insulin be attached onto magnetic nanoparticles without having its 
conformation affected by the attachment? 
1.4 Objectives and Scope of the Research 
Two specific research objectives were defined for this thesis: 
Objective 1:  Assessment of the feasibility of potential capturing techniques and analysis of the 
attachment of insulin onto the magnetic nanoparticles to confirm the attachment. 
Objective 2:  Measurement of the insulin’s conformation before and after it is attached with the 
magnetic nanoparticles. 
Clearly, the achievement of these two objectives will allow generating an answer to the research 
question of this thesis.  
This thesis was restricted to performing in-vitro experiments as specified in the statement of the 
objectives, and the bioactivity testing was not in the scope of the thesis. It involved the literature 
review to assess the feasibility of potential capturing techniques, experiment to attach insulin 
onto the magnetic nanoparticles and to perform various characterization experiments to confirm 
the attachment and to analyze the structure as well as conformation of insulin before and after the 
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attachment. It is important that insulin retains its native conformation after the attachment 
because any change in its confirmation might render it inactive going forward. This thesis was 
also expected to give a comprehensive overview of medical technologies for diabetes, including 
the medical science behind diabetes, insulin delivery, measurement of glucoses, and so on. This 
overview is necessary to enhance the understanding of the present work further.  
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Chapter 2: Literature Review 
2.1 Insulin 
Insulin is produced by an organ called pancreas. Pancreas has specialized areas called islets of 
Langerhans, which are made up of different types of cells that release hormones. The most 
common type of cells found in islets of Langerhans is beta cells, which produce insulin and 
release it into the blood stream. Beta cells also store insulin while producing it so that it can be 
released quickly if the need arises. The main function of insulin is to control the use of glucose in 
our bodies. Glucose is produced when our body breaks down the carbohydrates found in our 
food. Glucose is the main source of energy for our cells and insulin allows our cells particularly 
in our muscles, liver and adipose tissue to take glucose up from the blood stream and use glucose 
to produce energy. Any leftover glucose, not used by cells, is converted into glycogen, and 
stored as fat for later use, as shown by Step 4 in Figure 2-1 (yourhormones.info., accessed 
February 5, 2018; Wilcox, 2010). 
Insulin has a number of other functions as well and various cell types respond differently to 
insulin binding onto their surface receptors. Adipose tissue provides a unique example of this; 
instead of taking up glucose, cells in adipose tissue respond to insulin by taking up the fats in the 
blood stream and converting them into fatty acids (Wilcox, 2010).  
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Figure 2-1: Illustration of the insulin and glucose process (Wilcox, 2010). (1) Insulin binds to 
the insulin receptor, which (2) sends a signal to the glucose transporter, which (3) allows entry 
of glucose into the cell, then glucose can either (4) be stored as glycogen or (5) be broken into 
pyruvates, which can then lead to (6) fatty acids. Reproduced from the Nutrition Wonderland 
website (http://nutritionwonderland.com/2010/05/understanding-our-bodies-insulin/., accessed 
February 6, 2018).  
Besides directly controlling the level of glucose, insulin directs our body on a bigger level to stop 
digesting fats to produce energy. This leaves glucose in our blood and tissues as the main energy 
source. Insulin also plays an interesting role in our nervous system by stimulating our body to 
absorb a lot of its amino acids except tryptophan. This then leads to an increased concentration 
of tryptophan in blood stream, which makes it easier for tryptophan to cross the blood brain 
barrier. Tryptophan is used to produce another hormone, serotonin, in the brain, which functions 
to reduce appetite along with leading to a feeling of happiness. This is associated with the 
satisfaction that we feel after a good meal. Along with playing a part in regulating our emotions, 
insulin also has various effects on reproduction, which are not well understood at this time. Few 
of the examples mentioned above show that insulin is responsible for a lot more along with its 
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main function of regulating blood sugar levels and is far more important than initially perceived 
(Wilcox, 2010).  
2.1.1 Conformation as it Relates to Insulin 
Molecular conformation can be understood as a spatial arrangement of the atoms in a molecule, 
which can be interconverted. In biopolymers such as insulin the spatial arrangement of 
substituent groups makes up the molecular conformation. These substituent groups are free to 
assume different positions in space due to the freedom of bond rotation. Ethane is a relatively 
simple hydrocarbon and will be used as an example to further explain the concept of 
conformation. Carbon-carbon single bond in ethane provides nearly complete freedom of 
rotation around itself. This rotational freedom provides ethane with many different 
interconvertible conformations based on the angle of rotation. However, if we replace one of the 
ethane‘s hydrogens with another functional group with different properties the freedom of 
rotation will be hindered. This will result in a limited number of stable conformations that this 
ethane derivative can assume. One of the conformations will be more stable than others and the 
derivative will assume that conformation. Although insulin is much more complex than ethane, it 
also abides by the same rules. The different substituent groups on insulin determine its 
conformation. Changes in the environment such as temperature, pH, phosphorylation or binding 
of a ligand might induce a change in a biopolymer‘s conformation (Nature News; Lipid 
Biosynthesis; accessed September 2018).   
As a polypeptide insulin has four levels of structure: primary, secondary, tertiary and quaternary.  
Primary: In simple terms, the primary structure of any polypeptide basically displays the amino 
acids (AAs) that make up the polypeptide in their correct order of linkage. Insulin‘s primary 
structure contains two chains: Chain A which is comprised of 21 AAs and Chain B which is 
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comprised of 30 AAs. In total, the insulin molecule is made up of 51 AAs. AAs in Chain A and 
Chain B are connected to each other with peptide bonds. At one end of each chain there is an N-
terminal with a free amino group (-NH2) and on the other end there is a carboxylic group (-
COOH) (https://www.biotopics.co.uk/as/insulinproteinstructure.html.,accessed September 2018).  
Secondary: This refers to the next level of structure. The AA chains can form two distinct kinds 
of structural elements: alpha (α) helices or beta (β) pleated sheets. The third option is for them to 
link together without any distinct structure. The secondary structure of insulin is dominated by α-
helices. Chain A contains two sections of α-helices which have a relatively flat ribbon between 
them enabling them to essentially lie beside each other. Chain B seems to wrap around Chain A 
and consists of the larger section of the α-helix. Chain B also has smaller glycine residues which 
allow it to fold into a ―V‖ shape. This specific folding also allows for some Van der Waals 
interactions. Any change in the conformation or folding at this level will translate into a change 
in the higher levels of structure. This is why it is really important to investigate the secondary 
structure and confirm that polypeptides retain their native conformation at this stage 
(https://www.biotopics.co.uk/as/insulinproteinstructure.html., accessed September 2018).  
Tertiary: This level of insulin‘s structure involves further stabilization enabled via disulphide 
bridges. These bridges are formed between cysteine residues each of which has a thiol (-SH) 
group. Three disulphide bridges are formed in total: two between A and B chains and one within 
Chain A. At this level salt bridges also start forming and Van der Waals forces become more 
important as well (https://www.biotopics.co.uk/as/insulinproteinstructure.html., accessed 
September 2018).  
Quaternary: Insulin is usually stored in the form of hexamers (six insulin molecules grouped 
together). It may also be found in dimers (two insulin molecules grouped together). However, the 
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active form of insulin consists of a single insulin molecule 
(https://www.biotopics.co.uk/as/insulinproteinstructure.html., accessed September 2018).  
2.2 Insulin Regulation 
Although glucose levels are the principal stimulator of insulin secretion; a number of other 
molecules such as amino acids, proteins, lipids and other hormones like glucagon can similarly 
stimulate or inhibit insulin release. Also, there is an interesting and marvelous feature of human 
physiology, which stimulates insulin release even before we start eating. Just being in the 
presence of food, its smell, appearance, aroma, etc. can cause our brain to start a signaling 
cascade which triggers insulin release. This is called Cephalic Phase Insulin Release and its 
function is to prepare our body for what the brain sees as an oncoming flood of glucose. First 
Phase Insulin Release comes next as the food enters our body. Beta cells release all of the insulin 
that they had stored in reserves in a burst. The amount of insulin released here depends on how 
much insulin was needed in response to increased glucose levels that had resulted from a 
previous meal. If you needed more insulin last time, more will be released and if you needed less 
insulin, less will be released. Insulin release after this stage depends on whether or not the 
glucose levels have come back to normal. If more insulin is needed, it will be released otherwise 
beta cells will slowly take up some of the insulin that was released and the rest of it will go 
towards insulin degradation pathways (Wilcox 2010).  
Another hormone released by pancreas called glucagon has the opposite effect to that of 
insulin‘s. Glucagon‘s job is to raise blood glucose levels while insulin‘s job is to lower them. 
This comes into play if blood glucose levels fall too low and there is a risk of hypoglycemia. 
Insulin and glucagon work in tandem with each other, whereby insulin secretion inhibits 
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glucagon secretion and vice versa. This feedback system allows our body to tightly regulate 
glucose levels and make sure that they don‘t vary much from the homeostatic levels 
(yourhormones.info., accessed February 5, 2018). This feedback system is represented in Figure 
2-2.  
 
Figure 2-2: Illustration of the insulin-glucose-glucagon feedback system. Chain represented by 
the red arrows shows what happens when blood glucose levels are high, while the turquoise 
chain represents what happens when blood glucose levels are low. Reproduced from the 
Velocity PT Academy website (velocity-pt.co.uk., accessed June 15, 2018). 
2.2.1 Glucose Dependent Secretion 
Glucose is the primary stimulus for insulin secretion because it is a principal food component in 
many diets and accumulates quickly after ingesting food. Amount of insulin released in response 
to glucose versus other substances differs exponentially. Basal plasma level of insulin is 20-30 
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pmol/L and ingesting 75 g of glucose will raise this to 250-300 pmol/L in 30 minutes, while 
ingesting the same amount of fat and protein will only raise it to 50-60 pmol/L in humans 
(Chang et al., 1978). A number of evolutionary adaptions allow beta cells to continuously 
monitor the plasma glucose levels. These adaptions are coupled to rapid oxidative and 
anaplerotic metabolism which basically helps translate the signal resulting from increased 
glucose levels and maximizes production of adenosine triphosphate (ATP) which can be used for 
insulin secretion. Within the physiological range, beta cells are able to sense glucose because of 
their high Km glucose transporters and glucokinase. A high Km means that these transporters and 
glucokinase have lower affinity for glucose and have a smaller residence time at the binding site 
which results in higher turnover. Lower expression of lactate dehydrogenase, higher expression 
of redox shuttles, resulting in regeneration of reducing equivalents and increased pyruvate 
dehydrogenase and pyruvate carboxylase activity, also contribute towards having an efficient 
oxidative metabolism while glucose is present in abundance (Newsholme et al., 2012). In short, 
glucose impacts insulin secretion in beta cells via number of ways, with ATP generation and 
enhancement of oxidative metabolism being central to the process. 
2.2.2 Amino Acid Dependent Secretion 
Amino acid metabolism plays a major role in a number of cellular functions with protein and 
nucleotide synthesis being the most important. However, if administered as a nutrient source, 
they also have the ability to regulate insulin secretion. Effects of amino acids on insulin secretion 
are greatly dependent upon the type of amino acids administered, duration of exposure and 
concentration. Amino acids need to be administered in specific combinations in order for them to 
illicit a response. Under such circumstances, amino acids have the ability to regulate the 
triggering and amplification pathways of insulin secretion in a number of ways. Firstly, they can 
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serve as substrates for the oxidative cycle and redox shuttles resulting in ATP generation. 
Secondly, they can directly depolarize the cell membrane by transporting positively charged 
amino acids into the cell. Finally, they can also act as a co-transporter of sodium ions (Na
+
) once 
again resulting in depolarization of the membrane (Newsholme et al., 2012).  
2.2.3 Lipid Dependent Secretion 
Lipids also play a crucial role in beta cell function and insulin release; continuously increased 
lipid levels usually result in dyslipidemia and insulin resistance. Insulin resistance results in an 
increased need for insulin. This need is compensated by fatty acid potentiated insulin secretion. 
Also, during periods of starvation or fasting, lipids get metabolized in mitochondria of various 
cell types to produce ATP. The resulting energy from ATP can be used for insulin secretion 
(Chang et al., 1978; Newsholme et al., 2012).  
2.3 Insulin Degradation 
As it is apparent from its definition, the function of insulin clearance is to remove and inactivate 
the insulin in circulation after it has performed its action. A theoretical approach will dictate that 
insulin (or any other hormone) degradation is just as important as its secretion. All insulin-
sensitive cells and tissues have the ability to uptake and degrade insulin (Castillo et al., 1994). 
Although insulin clearance is a very complex process with multiple pathways, Insulin Degrading 
Enzyme (IDE) is thought to be the major enzyme driving this process (Duckworth et al., 1998). 
Insulin has a relatively short half-life of 7.5 – 9.5 minutes which is expected due to the nature of 
insulin‘s function and role as a hormone (Burt et al., 1974). Insulin clearance takes place in the 
liver, kidneys, extracellular environment and via cellular uptake of insulin and subsequent 
degradation. 
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2.3.1 Liver 
Liver is a major site of insulin clearance. The mean residence time of insulin is 71 minutes, out 
of which 62 minutes are spent bound to receptors in the liver that translates to about 80% of 
insulin being bound to liver receptors (Hovorka et al., 1993). Hepatic clearance of insulin is often 
affected by physiological and pathophysiological factors. For example, glucose ingestion results 
in increased insulin secretion which translates to increases in hepatic insulin uptake and 
decreases in patients with obesity and diabetes. Hepatic uptake and subsequent degradation of 
insulin relies mainly on a receptor-mediated process (Duckworth, 1988). However, during 
periods of high insulin concentration pinocytosis (non-receptor-mediated insulin uptake) also 
plays a significant role in uptake of insulin (Harada et al., 1992).  
2.3.2 Kidneys 
While liver plays a major role in clearing portal insulin, kidneys are the major players in clearing 
peripheral insulin from systemic circulation. Kidneys also remove about half of the circulating 
proinsulin (precursor of insulin) and also play a role in clearing a number of other insulin analogs 
(Rabkin et al., 1984; Kruse et al., 1997). Kidneys employ two mechanisms for insulin clearance: 
glomerular filtration and proximal tubular reabsorption. Glomerular clearance can occur via 
receptor-mediated transport or nonspecific diffusion. Proximal tubule cells in tubule lumen 
reabsorb almost all of the passing insulin via endocytosis (Nielsen, 1992).  
2.3.3 Cellular Insulin Uptake 
Cellular insulin uptake is a typical biological method with a number of steps. It starts with 
insulin binding onto to the receptor. This receptor bound insulin can then either be returned back 
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to the circulation intact or it can go to an intracellular site for degradation. Furthermore, there are 
multiple pathways for degradation of internalized insulin, which involve degradation in 
endocytotic vesicles. Degradation products can go to multiple subcellular sites such as the 
nucleus, golgi or even cytosol. Degradation can either take place at these sites or insulin is 
transferred to lysosomes. Most of the internalized insulin and its degradation products end up in 
lysosomes in order for degradation to be completed (Duckworth et al., 1998). Figure 2-3 shows a 
model of this process.  
Figure 2-3: Illustration of the cellular handling and degradation of insulin. (1) Insulin binds to 
its receptor; (1A) represents degradation right on the membrane; (2) possible release of intact 
insulin; (3) co-localization of insulin in plasma membrane; (4) formation of coated pits; (5) 
endocytosis; (6) initiation of endosomal degradation; (6A) intracellular processing of insulin 
and its degraded components;(6B) diacytosis of intact insulin or its degraded products; (7) 
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insulin or its degraded products are distributed intracellularly; (7A) cytoplasm, nucleus, golgi; 
(7B) lysosomes; (8) insulin delivery to lysosomes from organelles besides endosomes; (9) insulin 
receptor getting recycled; (9A) delivery of the receptor to the plasma membrane by diacytosis; 
(9B) insulin receptor back in its initial state. Reproduced with permission from W. C. 
Duckworth: Endocr Rev 9:319–345, 1988 (2 ). © 
2.4 Glucose Responsive Implantable Device 
As mentioned earlier exogenous insulin therapy is the main method employed by patients to 
manage their diabetes. However, there are various compliance issues associated with this method 
and more importantly it does not provide an accurate required dosage which can lead to poor 
clinical outcomes. Blood glucose levels cannot be predicted accurately mainly because of the 
variations in meals and body metabolism which can often lead to a higher or lower dosage 
response than is expected. Mostly the patients present with hypoglycemia (low blood sugar) due 
to an increased effect of the dosage. Glucose Responsive Implantable Devices have the potential 
to get rid of these limitations. They will provide an accurate release of insulin based on the close-
loop delivery principle. Glucose responsive implantable devices are a major step forward from 
the outside pumps that had been the center of attention before. Unlike an outside pump which 
detects the levels of glucose from the skin which subsequently results in a delay, these devices 
release insulin by detecting the actual blood glucose level within the body. Glucose levels are 
continuously monitored and based on the changes either the insulin release is initiated or it is 
inhibited or slowed down. In short, they provide closed-loop insulin delivery based on the 
glucose levels. Figure 2-4 depicts how these devices work in principle. 
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Weller et al. (1960) was the first to discover the fact that artificial pancreas could be used as a 
tool to save the effort of injecting patients at various intervals. Learning from Weller‘s research, 
Kadish in 1964 worked on developing the first portable insulin device which was actually more 
like a pumping machine. Although this system had a lot of limitations such as the absence of 
accurate computational aid to release insulin, it is still recognized as the first approach towards a 
closed-loop glucose responsive system. Weller‘s research and Kadish‘s initial attempt acted as a 
flame of fire to the oil in the realms of medical sciences which proved to be a door towards a 
whole world full of innovative techniques. Since then, many portable devices for glucose 
detection and acceptance have been designed and implemented to satisfy the thirst of gaining 
efficient clinical results. In 1970s Albisser et al. and Pfeiffer et al. took another step forward and 
navigated the world towards closed-loop delivery device. Both of these groups, independent of 
each other, developed a true artificial endocrine pancreas. They combined the continuous glucose 
Hyperglycemia 
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Figure 2-4: Illustration of the closed-loop insulin delivery principle. 
Closed-Loop 
Insulin Delivery 
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monitors with computational aids, a microcomputer with algorithms imbedded in it to automate 
the release of insulin. Further developments were made in the next two decades to make the 
devices more efficient and patient friendly. A number of algorithms were developed in hopes of 
mimicking the physiological secretion and inhibition of insulin. However, better methods were 
still needed because human body‘s responses in terms of metabolism cannot be predicted 
accurately by such an algorithm (Hovorka, 2006).  
Recently, research has been directed into overcoming the inadequacies of the previous devices 
through development of subcutaneous implant systems. In 2015 Chu et al. performed surface 
modification on their previous device using high molecular weight polyethylene glycol (PEG) 
and subcutaneously implanted it in rats to achieve a 3-fold increase in in vivo efficacy. Similarly, 
another group used subcutaneously implanted membranes constructed from a biocompatible 
polymer modified with a PEG monolayer and followed specific implant geometry and surface 
topography to achieve a functional lifetime of 21 days of their device (Li et al., 2015). However, 
a major shortcoming of subcutaneous systems is that they lack in speed and stability of insulin 
delivery in comparison to the physiological system. Intraperitoneal insulin delivery has faster 
kinetics and better stability and reliability than the subcutaneous route (Burnett et al., 2014; 
Renard, 2008; Renard et al., 2011). Thus, Taylor et al. tested an intraperitoneal implant in a 
domestic pig with induced diabetes and were able to achieve normoglycemia for about a month. 
The pig was terminated before the insulin was refilled due to a peritoneal infection (Taylor et al., 
2016). Thus, ways to prolong implant functionality in the intraperitoneal cavity should be 
investigated in order to minimize invasive procedures for replacement/refilling of insulin 
reservoirs while maintaining the speed and reliability of intraperitoneal insulin delivery systems. 
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2.5 Review of Potential Capturing Techniques 
2.5.1 Immunoprecipitation 
Immunoprecipitation was developed as the next step in the Traditional Column Affinity 
Chromatography (TCAC). TCAC used a packed column of porous resin which had target-
specific antibodies attached onto it. The samples would then pass over this resin and the 
immobilized antibody would form a complex with its antigen (target proteins or biomolecules). 
However, IP doesn‘t rely on a packed column and it involves a number of incubation steps and 
uses only a small amount of resins in a microcentrifuge tube. Immunoprecipitation uses an 
antibody which specifically binds to an antigen and precipitates it out of the solution of many 
antigens. The most widely used application of IP is the small-scale affinity purification of 
antigens using specific antibodies which are immobilized onto solid supports such as an agarose 
resin or magnetic particles. Although a variation of IP called co-immunoprecipitation can be 
used to study the protein-protein interactions, in its simplest form, and for our purposes as well, 
IP is used to isolate a single antigen.  
IP assays can be performed in one of the two ways: either by using a pre-immobilized antibody 
on a highly porous agarose or solid magnetic beads which are then incubated with the solution 
containing the antigen or by using non-bound antibody which can form complexes with the 
antigen which are then retrieved by the beads. As Figure 2-5 depicts, the result using both 
methods would be same. Up until the recent past, majority of the IPs were performed using 
agarose beads, but now the use of magnetic beads has become more common. The reason for it is 
the ease of use, reproducibility, increased purity and speed. Overall, each method has its benefits 
and drawbacks and the final decision is ultimately based on the target protein and the type of IP 
assay to be used (thermofisher.com., accessed February 15, 2018). 
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Figure 2-5: Illustration of immunoprecipitation using pre-immobilized (left) and free (right) 
antibodies (thermofisher.com., accessed February 15, 2018). 
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Magnetic Beads versus Agarose Resin  
Initially IPs were performed using small aliquots (10-25 µL) of agarose resin in microcentrifuge 
tubes. After the incubations, centrifugation is used to separate the agarose beads from solution. 
The easiest way to do this is to use a microcentrifuge filter cup which retains the beads and 
collects rest of the solution in the tube. A more time consuming technique involves pelleting the 
beads and carefully pipetting off the solution. These characteristics of agarose resin prevent it 
from being used in experiments which require significant automation or scaling down. These 
limitations have led the agarose resin to be replaced by magnetic particles such as Dynabeads or 
Pierce Magnetic Beads. Antibodies can only bind to the surface of each solid and spherical 
magnetic particle. Magnetic beads make up for this limitation because of their significantly 
smaller size (1-4 µm) compared to agarose beads (50-150 µm), which collectively give them 
increased surface area. High power magnets are then used to localize the beads to the side and 
rest of solution can easily be poured or pipetted out. This eliminates the need for centrifugation 
which can break off relatively weak interactions between antibody-antigen resulting in loss of 
target antigen. This process can be fully automated (thermofisher.com., accessed February 15, 
2018). 
As mentioned before, IP techniques are mainly used to isolate a certain antigen in-vitro for 
further analysis. It will be relatively easy to isolate insulin from a cell or tissue lysate using the 
IP techniques. However, for our purposes this is where IP use is limited to, and we need further 
capabilities.  
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Magnetic Beads 
For the purpose of this research, an insulin specific antibody would have been used, which would 
help with isolating the insulin, so insulin won‘t be degraded, and then later collected to be 
released once again when needed. The collection part suggests that using the superparamagnetic 
beads would be a better option in the experiment, since the insulin-antibody complex would need 
to be pulled back to the insulin device and a magnetic field could be used to achieve this. 
Although in theory this approach seems to be sound, its limitations prevent us from using this 
technique. First of all, magnetic beads are only recommended for small sample sizes of about 
2mL, which suggests some doubts regarding its use in the circulating blood of much greater 
volume. Second, the use of magnetic beads in IP requires the use of high power magnetic 
equipment which can prove to be quite cost prohibitive. Also, this process requires the process 
conditions or environment to be very specific in terms of the required pH, temperature, bead size, 
etc. Any variations in these parameters could prevent the beads from localizing onto the magnet. 
For a long term use, magnetic beads coated with antibodies need to be stored at a temperature 
range of 2
o
 - 8
o
 C, otherwise they will lose the antigen binding capacity (thermofisher.com., 
accessed February 15, 2018). It is virtually impossible to mimic such conditions inside a human 
body for long periods without significantly affecting other functions of the body.  
Agarose Resin 
Using this technique only gives us the opportunity to isolate insulin and prevent it from 
degradation. There is no feasible approach which allows the insulin from the agarose resin to be 
pulled back to the implanted device. Gel bed like agarose resin structures will need to be placed 
at various insulin clearance sites so that they can capture insulin before it gets to liver or kidneys 
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for degradation. Agarose resin does allow us to work with a larger sample size, however 
accessibility to antibodies is sometimes diminished in these resins because of their sponge like 
structure. This approach also requires longer incubation periods, and this might not be possible 
due to insulin‘s bioavailability after it has affected its action. This technique also requires very 
specific conditions to work efficiently (thermofisher.com., accessed February 15, 2018). 
Main reasons for not using IP 
The use of immunoprecipitation is highly dependent upon the specificity of the anti-insulin 
antibody used. This rules out the use of polyclonal antibodies which can bind to different sites on 
the same antigen. They might bind to other protein complexes which might have the same 
epitope in their long amino acid chains. A significantly more expensive monoclonal antibody 
will need to be produced, which will actually have a lower affinity for insulin as it can only 
recognize one site or epitope on insulin. Due to this limitation, monoclonal antibodies require 
longer periods of time to capture the target protein, which as mentioned before might not be 
feasible due to insulin‘s relatively short bioavailability. Monoclonal antibodies are also more 
sensitive to changes in their environment, and this might render them unable to detect insulin 
(pacificimmunology.com., accessed February 15, 2018). The biggest reasons lie within the 
processes that might be required to dissociate insulin from the insulin-antibody complex so it can 
be used again. Currently no gentle methods are available to achieve this dissociation; indeed, 
extreme pH and temperature changes or the use of toxic chemicals is required to achieve this. 
Since the long term approach for this idea is to be used in vivo, implementing these extreme 
changes or the use of toxic chemicals will not be feasible as they will interfere with rest of the 
homeostatic systemic circulation as well. The dissociation process also does not guarantee the 
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functionality of insulin or the antibody after dissociation as in most cases it results in 
denaturation of the antibody and antigen.  
Our research group was collaborating with abcam, a company that specializes in antibodies and 
their use in various techniques including IP, to look for specific antibodies that would comply 
with our requirements. A lot of their polyclonal antibodies were ruled out based on our 
requirement of specificity. For any of their polyclonal or monoclonal antibodies, currently, no 
protocol is available that will allow us to dissociate insulin from the antibody. An extensive trial 
and error would be required to find a suitable dissociation procedure, which might still not be 
feasible to use in vivo. In literature, there are conflicting views regarding using the same 
antibody more than once and antibodies available at abcam will once again require extensive trial 
and error to figure out whether or not they can be reused and how many times they can be 
reused. Based on the extensive amount of extra work and resources required to consider and 
address various complications and variations that might arise using IP our research group 
decided it to not be a feasible approach for our purposes.  
2.5.2 Nanomedicine in Diabetes Management (Magnetically Charged Nanoparticles) 
Over the past few decades, starting with the FDA approved application in cancer treatment 
(Barenholz, 1995), incorporation of nanotechnology in novel diagnostic and treatment strategies 
in various medical fields has improved their efficacy immensely. Nanotechnology‘s successful 
employment in cancer treatment and various other diseases including cardiovascular diseases lit 
an ever spreading fire in the realm of medicine. Researchers found the chemical, physical and 
biological properties of materials produced from nanotechnology, such as nanoparticles, very 
tempting for use in medicine and numerous other biomedical applications (Whitesides, 2003; 
Lavan et al., 2002). Since then a lot of nanoparticle formulations have been produced for use in 
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medicine, including magnetic or polymer nanoparticles, stimuli responsive nanoparticles and 
various other nanostructures including nanofabricated devices (Kudr et al., 2017). Appreciation 
for these products of nanotechnology has found its way in diabetes management as well. Current 
developments include noninvasive monitoring of disease progression and blood glucose levels, 
glucose responsive insulin therapy and improvements in immune modulation for cell based 
therapies (Veiseh et al., 2014). Nanomedicine based approaches provide immense potential for 
improving the management of diabetes in patients with Type I or Type II Diabetes.  
Applications in Diagnosis and Disease Monitoring 
Research indicates that earlier diagnosis and treatment of diabetes may be beneficial to disease 
management (Simmons et al., 2010). Pancreatic β-cell mass is an indicator of disease progression 
and will facilitate an understanding of the development and course of diabetes, as there is a 
reduction in the cell mass with progression of diabetes (Matveyenko et al., 2008). However, β-
cell mass cannot be directly measured in vivo in humans. Currently, downstream measures of β-
cell mass are used, such as C-peptide levels or insulin requirements. Autopsy studies are required 
for direct measurement of β-cell mass, which are post-mortem and confounded by several factors 
such as limited dissection of the pancreas (usually only the pancreatic tail) and changes in β-cell 
mass associated with the final illness leading to death (Fogar et al., 1994; Chari et al., 2005). 
Advancements in molecular imaging have made β-cell mass measurements in vivo possible 
through development of β-cell-targeting peptide dyes (Reiner et al., 2011) and antibody-dye 
conjugates (Moore et al., 2001), but these techniques require invasive procedures to access tissue 
samples. Several noninvasive imaging techniques for the purpose of β-cell mass measurement 
are being investigated, such as computed tomography (CT), positron emission tomography 
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(PET), magnetic resonance imaging (MRI) (Andralojc et al., 2012). In addition, magnetic 
nanoparticle (MNP) probes with β-cell specificity that act as contrast agents have been 
developed to facilitate β-cell imaging (Medarova et al., 2009; Wu et al., 2010). Specifically, 
superparamagnetic iron oxide nanoparticles (SPIONs) can aid visualization of β-cells via MRI. 
In a small clinical trial, patients with recent-onset type 1 diabetes were infused with a SPION-
based contrast agent called ferumoxtran-10. MRI of SPIONs in these patients allowed 
visualization of the pancreas and revealed differences between patients with recent-onset 
diabetes and healthy controls associated with islet inflammation (Gaglia et al., 2011). This 
technology was exploited as a prediction tool in a future study to achieve early diagnosis of 
diabetes in young mice through detection of immune cell filtration followed by pancreatic-islet 
inflammation (Fu et al., 2012). It has further potential to monitor the progression of diabetes and 
assess effectiveness of experimental therapies early in the trial. The early response to an 
immunomodulatory intervention was monitored using this technology in diabetic mice (Turvey 
et al., 2005).  
Though these advancements in pancreatic imaging are promising for diabetes diagnosis and 
monitoring of disease progression, further research is required to develop biomarkers that report 
β-cell stress or dysfunction. This will facilitate assessment of the effectiveness of therapies and 
inform categorization of patients by disease severity for targeted therapies.  
Applications in Glucose Sensors 
Blood glucose levels allow monitoring of the disease to inform therapies as diabetes progresses 
and predict complications associated with diabetes. Therefore, highly sensitive glucose 
biosensors that monitor BG levels would be beneficial to fundamental diabetes research. 
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Currently, handheld glucose meters that use blood samples collected via finger pricks are most 
commonly used to measure BG levels (Schmid et al., 2013). However, this method is painful, 
permits only intermittent testing, and makes it possible to miss episodes of hyper- and 
hypoglycemia that occur outside of the testing times. Therefore, subcutaneously implanted 
amperometric sensors called continuous glucose monitors (CGM) that sample interstitial fluid 
have been developed (Mauras et al., 2013). Though CGMs allow for continuous testing, issues 
remain with accuracy and usability; CGM measurements lag 5-15 minutes behind BG levels, 
CGM implantation requires an invasive procedure, and the CGMs need to be replaced frequently 
(Hovorka et al., 2013). Research has been directed to develop glucose sensors that can overcome 
the shortcomings of the conventional glucometers and CGMs.  
For instance, amperometric glucose sensors went through multiple generations of improvement. 
The first generation of glucose sensors employ oxygen as an electron mediator between glucose 
oxidase and an electrode, where glucose oxidase enzymatically reduces oxygen into hydrogen 
peroxide in the presence of glucose (Hovorka et al., 2013). The rate of this reaction is 
proportional to the glucose concentration. Though a continuous readout of glucose concentration 
is possible with the first generation sensors, they are dependent on oxygen and may be interfered 
by competing redox-active species. The second generation sensors overcame the oxygen-
dependency by using artificial mediators such as ferro/ferricyanide but still risked interference by 
other redox-active species that may be present (Cass et al., 1984). The third generation sensors 
were based on electron transfer directly between glucose oxidase and the electrode, proposed by 
Heller and Degani (Degani et al., 1987; Heller, 1990), because it eliminated the possibility of 
interference.  
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Next, nanosensors with glucose oxidase built onto surface of metallic nanoparticles (palladium, 
gold, and platinum) and carbon nanotubes were developed because they have a large specific 
surface area and improved biocompatibility (Zhang et al., 2005; Tang et al., 2004; Claussen et 
al., 2010). Though these sensors were an improvement, inherent drawbacks associated with 
glucose oxidase remained; glucose oxidase activity can diminish over time (Hoedemaekers et al., 
2008) and be affected by changes in oxygen level, pH, and temperature (Bankar et al., 2009). 
These limitations led to investigation of nonenzymatic nanosensors. For instance, sensors relying 
on metal oxide catalysts such as copper oxide (Bankar et al., 2009; Pickup et al., 2005) or gold 
nanoparticles (Hussain et al., 2011) to oxidise glucose have been developed. These sensors use 
applied voltage to drive reactions and thus require batteries, making them bulky and 
inconvenient for patients. Sensors using glucose-binding moieties, including lectins (Schultz et 
al., 1982; Liao et al., 2008); synthetic molecules such as phenylboronic acid (PBA) (Chen et al., 
2011; Kataoka et al., 1995); and polyacrylamide- (Yang et al., 2011) and polyallylamine-based 
(Yang et al., 2011; Parmpi et al., 2004) hydrogels have also been explored. Nanoparticles such as 
carbon nanotubes (Barone et al., 2009; Yum et al., 2013) or nano-optodes (Balaconis et al., 2011; 
Billingsley et al., 2010) in association with the glucose-binding moieties may be able to represent 
glucose binding to the moiety as a voltammetric or fluorescent output. Single-walled carbon 
nanotubes and semiconducting quantum dots have been shown to produce a fluorescent output in 
such sensors (Bull et al., 2012; Klonoff et al., 2012). Such sensors are patient-friendly, as they do 
not require batteries and thereby may have higher longevity in vivo. They are also more 
promising than previously mentioned sensors because they do not rely on an enzyme-based 
catalyst and have the potential to provide rapid readouts.  
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Despite these advantages, further research is required to develop nanosensors with fluorescent or 
voltammetric outputs for clinical use. The safety of carbon nanotubes is questionable (Saito et 
al., 2014), device biocompatibility must be achieved, and calibration of fluorescent output needs 
to be accomplished across variations in skin such as color and hair thickness.  
Applications in Insulin Delivery 
 Nanotechnology offers unique advantages in insulin replacement therapy by improving its 
efficacy, safety and ease of use which results in greater patient compliance (Krol et al., 2012; Zhi 
et al., 2013). Research has also been focused on developing long-acting nanoparticulate insulin 
formulations to minimize the frequency of injections (Peng et al., 2012) while other research has 
focused on even more novel ideas that can possibly lead to development of less invasive routes 
of insulin delivery. As mentioned above, ever since the production of the first glucose-responsive 
insulin system, the interest in developing glucose-responsive insulin formulations that 
incorporate nanotechnology has increased immensely. Along with increasing the reliability of 
glucose level detection the glucose sensors mentioned above can also be incorporated into 
insulin delivery systems making them glucose-responsive.  
The biggest advantage that the glucose-responsive insulin delivery systems provide is the ability 
to much more closely mimic the physiological insulin cycle in response to changes in blood 
glucose levels. This will lead to tighter glycaemic control and will result in decreased 
hypoglycaemic periods. Nanotechnology pertaining to insulin delivery systems has matured very 
rapidly resulting in advancements that allow researchers to develop insulin carrying nanoparticle 
formulations that can respond to changes in their environment and subsequently release their 
cargo (Fleige et al., 2012). There are multiple ways by which a nanoparticle can be made to be 
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sensitive to the fluctuating glucose levels in its environment. The most commonly used approach 
involves the use of glucose-sensing triggers such as glucose oxidase, glucose-binding proteins or 
any other glucose-binding small molecules. Nanoparticle formulations using these triggers 
respond to increased glucose levels through swelling, degradation or disassembly which results 
in insulin release (Stuart et al., 2010; Wu et al., 2010). One of the ways that glucose-sensitive 
nanoparticles can be engineered is by combining glucose imprinted polymers with glucose-
binding proteins such as concanavilin A (ConA) to form supramolecular assemblies that are 
glucose-responsive (Yin et al., 2014). Figure 2-6 below shows how glucose-sensing triggers such 
as ConA can be integrated into the nanoparticle that is engineered to swell or degrade in response 
to increased glucose levels.  
 
Figure 2-6: Illustration of glucose-imprinted polymer combined with concanavilin A (ConA) to 
form a supramolecular assembly which is responsive to glucose (Veiseh et al., 2014). 
Glucose-binding proteins such as ConA have high specificity for glucose and provide reliable 
binding. However, this approach has a drawback, glucose-binding proteins can be seen as foreign 
entities by the body and limited progress has been made in trying to get rid of this limitation. 
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Perhaps because of this reason most of the research has focused on the approaches based on 
glucose oxidase and in part due to its high specificity for glucose (Veiseh et al., 2010).   
Magnetically Charged Nanoparticles 
Magnetically charged nanoparticles (MNPs) are a class of non-invasive therapeutic agents that 
can be used for imaging, cellular-specific targeting and drug delivery. Recent advances in this 
realm have made them irresistible for use in various biomedical and therapeutic applications. 
One of the main reasons for their irresistibility is their intrinsic magnetic properties. MNPs 
comprise of nanoparticles that make use of their metallic, bimetallic or superparamagnetic iron 
oxide (SPIONs) cores (Sun et al., 2008; Mcarthy et al., 2008). SPIONs have garnered most of the 
attention due to their relatively lower toxicity (Lewinski et al., 2008; Wang et al., 2001; 
Lawrence, 1998) and more importantly their reactive surfaces which can be modified with 
biocompatible coatings (Gupta et al., 2005; Gupta et al., 2007; Laurent et al., 2008; Misra, 2008) 
combined with imaging, targeting and therapeutic molecules (Laurent et al., 2008; Misra, 2008; 
McCarthy et al., 2007; Dobson., 2006). These properties have allowed successful SPION usage 
in magnetic separation (Pankhurst et al., 2003), biosensors (Zhao et al., 2006; Perez et al., 2002), 
medical imaging (Sun et al., 2008; Frullano et al., 2007; Corot et al., 2006), drug delivery 
(Dobson, 2006; Duran et al., 2008), tissue repair (Solanki et al., 2008) and hyperthermia 
(Thiesen et al., 2008) applications. A few of these SPIONs are already in early clinical trials or 
experimental study stages (Sun et al., 2008; Mcarthy et al., 2008; Laurent et al., 2008) and some 
have even been approved for clinical use in medical imaging and therapeutic applications. In its 
most simple form a MNP consists of a magnetically active core which is coated with a stabilizing 
shell. At this stage, any required targeting ligands, imaging modalities or therapeutic agents can 
be anchored to its surface in order to achieve the desired function (Veiseh et al., 2010). In order 
33 
 
to create SPIONs that are capable of targeting and or eliminating tissue (if it is damaged) very 
detailed attention needs to paid to their design parameters such as size, shape, coating and 
surface modifications (Dobrovolskaia et al., 2008; Chouly et al., 1996). Only with such careful 
engineering can you create nanoparticles that are able to overcome various biological barriers 
and carry out their functions. The drug delivery systems require additional consideration given to 
interactions between nanoparticles and target cells and the controlled release of the drugs 
(Veiseh et al., 2010). 
Design Considerations: Before researchers can begin the synthesis of MNPs, they must 
understand the nature of nanoparticles as pharmaceutical or therapeutic constructs that must 
travel through the body to find their target, can overcome various biological barriers in the 
process and their design parameters in order to develop an effective and efficient MNP system.   
In Vivo Barriers: Human body‘s defense system has created a number of so called biological 
barriers in order to protect itself from foreign entities entering the body, which coincidently 
include injected therapeutics or any other agents, and very successfully prevents them from 
reaching their target destinations (Ferrari, 2005). These biological barriers have the ability to 
significantly hinder nanoparticle function up to a point where they can be rendered non-
functional and be secreted out of the body. The body‘s defense system does so by inhibiting 
nanoparticle movement, causing physical changes to them or by inducing a negative host 
response using a number of biochemical signaling pathways (Belting et al., 2005). Nanoparticles 
first come into contact with blood once they are injected. Here, the heterogeneity of blood can 
cause nanoparticles to agglomerate resulting in alterations to their magnetic properties ultimately 
leading to their sequestration. There is also a possibility of nanoparticles interacting with plasma 
proteins or various other non-targeted cell surfaces (Davis et al., 2002). Each one of these 
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barriers poses a threat of non-targeted premature binding and possible endocytosis of 
nanoparticles before they can reach their target.  
These barriers can also present themselves in terms of various anatomical size restrictions which 
the nanoparticles must comply with in order to reach their target cells (Ferrari et al., 2005). One 
particular example refers to the interaction of nanoparticles with the blood brain barrier (BBB). 
Besides posing very strict physiochemical restrictions on the nanoparticles, BBB only allows 
nanoparticles with a sufficiently smaller size to pass through (Koo et al., 2006). A lot of 
nanoparticles have been engineered that can overcome these extracellular barriers and 
successfully bind to the surface of their target cell which in many cases initiate receptor-
mediated endocytosis. Once inside the cell, they must now face intracellular barriers as well. A 
number of physiological pathways here can lead to acidification of endosomes resulting in 
destruction of the nanoparticles that are carried inside (Bareford et al., 2007). Nanoparticles can 
also be translocated from endosomes into lysosomes where hydrolytic and enzymatic reactions 
can completed metabolize them. As long as researchers are mindful of these biological barriers 
and see them as demands put upon the engineering of nanoparticle core and surface properties, 
they can overcome all of these limitations (Veiseh et al., 2010).  
Physiochemical Considerations: Nanoparticle‘s in vivo functionality is largely dependent upon 
its physiochemical properties which include its morphology, size, charge and various other 
surface properties. All of these properties must be considered at each stage of MNP design and 
how they will contribute to its overall physiochemical properties (Veiseh et al., 2010). For 
instance the shape of MNPs can have significant effects on their bio-distribution and even their 
bioavailability. One research study suggests that anisotropically shaped MNPs are better at 
avoiding bio-elimination compared to their spherical counterparts (Liu et al., 2006) which 
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subsequently results in longer bioavailability. Another study showed that increased length-to-
width aspect ratio of MNPs results in increased blood circulation time (Geng et al., 2007). 
Variations in hydrodynamic size of MNPs can have similarly significant effects on their 
bioavailability and distribution as well. Research has shown that hydrodynamic size of 
nanoparticles helps in governing their concentration profile in blood vessels (Decuzzi et al., 
2005; Decuzzi and Ferrari, 2006; Decuzzi and Causa, 2006), plays a significant role in their 
clearance from circulation (Long mire et al., 2008; Choi et al., 2007; Moghimi, 1995; Mogimi, 
Hunter et al., 2001; Zamboni., 2008; Moghimi, Moein et al., 2001) and most obviously dictates 
the permeability of nanoparticles (Chavanpatil et al., 2006).  
Other surface properties of nanoparticles such as charge and hydrophobicity or hydrophilicity 
can also have major effects on their interaction with the in vivo environment. These properties 
can either limit or enhance nanoparticle interactions with the immune system, plasma proteins, 
extracellular matrices and non-targeted cells (Davis, 2002). Various studies have shown that 
charged and/or hydrophobic nanoparticles have shorter circulation times due to enhancement of 
these interactions (Chouly et al., 1996). Positively charged nanoparticles are also at the risk of 
binding with non-targeted negatively charged cells which can prevent them from reaching their 
target site (Veiseh et al., 2010). However, research over the past few years has led to the 
development of stealth nanoparticles whose surfaces are modified with molecules like 
polyethylene glycol (PEG) resulting in prolonged circulation times (Harris et al., 2003). Some 
other organic surface coating molecules include dextran, chitosan, liposomes, micelles and 
copolymers. All of these molecules function to serve a similar purpose (Veiseh et al., 2010).  
Specifically, variations of PEG have been used in a number of FDA approved pharmaceutical 
formulations (Fuertges et al., 1990). These variations are neutral and hydrophilic and function to 
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improve the dispersity and bioavailability of MNPs based on the principles mentioned above. 
MNPs that have been coated with PEG are commonly referred to as stealth nanoparticles because 
of their increased ability to evade detection by the reticuloendothelial system (RES) (Harris et 
al., 2003). Although this limits their usage in imaging RES related cells (Papisov et al., 1993), it 
makes them perfectly suitable for use in target-specific cell labeling following modification with 
targeting ligands (Sun, Fang et al 2008; Sun, Veiseh et al., 2008; Chen et al., 2007). MNPs used 
in this research have been coated with a variation of PEG called polyethylene glycol diacrylate 
(PEGDA). The design process follows from a polymeric design strategy that considers both: 
efficient surface coating and functionalization (Veiseh et al., 2010). This idea was first 
researched by Kohler in early 2000s (Kohler et al., 2004). He was able to prepare a variation of 
PEG that could be attached to SPION surface via covalent bonding at one end and the other end 
could be functionalized by any of the various therapeutic agents or targeting ligands (Sun, Fang 
et al 2008; Sun, Veiseh et al., 2008; Sun et al., 2006; Veiseh et al., 2005; Gunn et al., 2008; 
Veiseh et al., 2008).   
Directing nanoparticles in vivo: Variations of passive, active and magnetic targeting have been 
used to direct the travel of nanoparticles inside the body (Veiseh et al., 2010). First of the three, 
passive targeting, does not require an input of energy, instead it makes the use of a certain 
nanoparticle‘s predetermined physiochemical properties to guide its path to the target cell or 
tissue. Cancer research involving nanotechnology has seen use of this passive approach. Solid 
tumor tissue can be targeted relatively easily by passive targeting due to its certain properties. In 
most cases the goal of tumor cells is to grow rapidly which requires the production of new blood 
vessels. To achieve this rapid growth, the neovasculature that is produced quickly is usually 
poorly organized and contains leaky fenestrations. Along with other small macromolecules, 
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nanoparticles can use these fenestrations to enter the tumor cells (Jain, 1999 and 2001). Another 
effect of this hurried growth is the development of an inefficient lymphatic drainage, which 
results in lower clearance of the nanoparticles that have entered this vasculature resulting in their 
accumulation at these sites (Hobbs et al., 1998; Mcneil, 2005). This overall phenomenon is 
known as enhanced permeation and retention (EPR) (Maeda et al., 2000). However, the 
successful application of EPR is dependent upon a number of things including degree of 
fenestration and lymphatic drainage rate and its use is limited to specific solid tumors (Veiseh et 
al., 2010).  
Due to the limitations of passive targeting further modification of nanoparticles was pursued. As 
mentioned above, surfaces of nanoparticles can be modified with molecular ligands such as PEG; 
additional modification can also be done using specific molecular targeting ligands. This overall 
approach represents, second of the three approaches mentioned above, active cell targeting 
(Zhang et al., 2002; Sinha, 2006). These targeting ligands are complementary to unique receptors 
on surfaces of the target cells and therefore, actively target only the diseased cells. Successful 
application of the active cell targeting depends upon the type of ligand used and its density and 
by the size and shape of the nanoparticles. These factors become even more important because of 
their role in the multivalency phenomenon. Multivalency refers to the enhanced binding avidity 
phenomenon observed when multiple targeting ligands bind to multiple receptors between two 
surfaces at the same time (Wright et al., 2001; Munson et al., 1979). A research study done in 
mid 2000s showed the role that the multivalency phenomenon plays in nanoparticle binding. It 
indicated that the density and molecular organization of the targeting ligands on nanoparticle‘s 
surface has a major role in its binding to the target cell (Hong et al., 2007). Simultaneous ligand 
binding increases with increasing the density of the targeting ligand, but only up to a certain 
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limit, after that multivalent interactions could be sterically hindered (Montet et al., 2006). Figure 
2-7 shows how nanoparticle size and shape along with ligand density might affect the 
multivalency. Illustrations depicted in Figure 2-7 are based on the work of Jiang et al (Jiang et 
al., 2008). This study looked at nanoparticles ranging in size from 2 nm to 100 nm. Nanoparticles 
under the size limit of 25 nm do not possess the ability to be multivalent as their size permits 
them from having multiple ligands on their surface. Conversely larger nanoparticles do possess 
the ability to be multivalent, but they face difficulty in the endocytosis process which limits their 
functionality for certain applications. Nanoparticles of 25 – 50 nm size were shown to be most 
efficient as they can show multivalency binding effects and can be endocytosed relatively easily. 
Our research group used nanoparticles of two different sizes, 200 nm and 500 nm for 
comparison. As insulin receptors are found on the cell surface our research group was more 
concerned with their ability to be multivalent rather than any issues associated with endocytosis. 
In fact, for the bigger picture concept we would prefer to have nanoparticles that cannot be 
endocytosed as it will increase their bioavailability. Insulin receptors are found on the surface of 
the cells. Therefore, there is not a need for them to be endocytosed. A bigger size of 
nanoparticles prevents them from endocytosis and might even provide even longer 
bioavailability.  
Finally, researchers have also used external magnetic systems to guide MNP localization in an 
approach called magnetic targeting (Dobson, 2006; McBain et al., 2008). Powerful magnets are 
used to create a magnetic field which can result in accumulation of MNPs within that area. One 
limitation of this approach is that it becomes less and less effective as you go deep into the body 
due to the loss of magnetic field strength. Studies that have seen optimal use of this technology 
focus on target sites that are closer to the skin because of the higher strength of the magnetic 
39 
 
field as the area is closer to the magnetic source. 2004 saw successful implementation of this 
approach in a clinical trial aimed at delivery doxorubicin, a chemotherapeutic agent, to 
hepatocarcinoma cells (Wilson et al., 2004).  
Figure 2-7: Illustration of the multivalent capabilities of different sized MNPs. Illustration on the 
left represents nanoparticles of ~ 25nm, in the middle represents nanoparticles of 26 – 70 nm 
and on the right represents nanoparticles of 71+ nm and their multivalent abilities. 
Other Considerations: As mentioned before nanoparticles used for drug delivery require some 
additional considerations given to drug loading and release. First of all, MNPs created for drug 
delivery must have the capability to carry and protect the drug payload. The type of MNP 
coating and loading method (e.g. covalent bonding, linker/click chemistry or physical 
interactions such as any affinity interactions) determine the MNP‘s ability to carry and protect 
the payload (Veiseh et al., 2010). Secondly, the MNPs carrying drugs must be able to overcome 
the cellular drug resistance. Multiple drugs can be loaded onto a single MNP to help in 
overcoming this resistance. However, loading multiple drugs requires planning to accommodate 
the different therapeutic agents (Veiseh et al., 2010). Finally, the drug release mechanism must 
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be optimized in order to achieve maximal efficacy. Different approaches have been used to 
optimize the drug release ranging from predetermined drug release to the use of a feedback loop 
(drugs released in response to certain changes in the cellular environment). Figure 2-8 below 
shows the basic structure of a multifunctional imaging/therapeutic MNP and the local activity of 
different categories of therapeutic agents. MNPs designed for such dual applications may carry 
targeted moieties attached to polymeric tethers (e.g. PEG), multiple imaging agents (optical, 
radio or magnetic) and other bio- or chemotherapeutic agents. Once in vivo; different 
mechanisms can be activated dependent upon the choice of therapeutic agents used.  
One of the final things that needs to be considered in MNP design is the matter of toxicity to the 
body. In order to make sure that a nanoparticle system does not pose any threat to the human 
Figure 2-8: Illustration of the basic structure of a multifunctional MNP and the local activity of 
different therapeutic agents. (A)  Basic Structure, (B) Local intracellular activity, (a) MNP 
binding to surface receptors, (b) controlled release of chemotherapeutics, (c) decay of 
radioactive materials, (d) controlled release of gene therapeutic materials. 
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body, toxicity of all of the individual components and the nanoparticle as a whole must be 
evaluated. This is necessary because we need to consider how a nanoparticle will interact with 
the body during its bioavailable phase and also after its degradation starts and individual 
components start getting excreted (Lewinski et al., 2008).  
Surface Modification: Various chemical approaches have been employed to achieve the 
tethering of imaging, targeting or therapeutic agents onto nanoparticles. Most of these 
approaches can be divided into two categories: covalent linkage strategies and physical 
interactions. The approach used depends mainly on the chemical properties and functional 
groups present on the coating polymers and the ligand to be attached. The primary goal of the 
surface modification chemistry is to attach the agent without compromising its functionality 
which is, in part, determined by the manner in which the ligand is attached to the nanoparticle. 
For example, in case of antibodies, if they are attached in such a way that their recognition site is 
hindered or shielded, they will lose their ability to bind to the antigen (Veiseh et al., 2010).  
Covalent linkages are strong and stable bonds that are formed between functional groups on the 
nanoparticle surface and the conjugated ligands. Usually the functional groups, typically amino, 
carboxylic acid and thiol groups, are added to the nanoparticle surface through its polymer 
coating. The type of polymer coating used determines the type and number of functional groups 
present on the surface of nanoparticles. These functional groups can either be part of the body of 
the polymer (e.g. chitosan) or they can be found at their terminal ends (e.g. PEG). These 
functional groups are also present on the imaging, targeting or therapeutic moiety to be attached. 
There are three methods available to create a covalent linkage, and first one is called direct 
nanoparticle conjugation. In this approach, the functional groups on the nanoparticle surface are 
either directly bonded to the moieties or a linkage reaction is facilitated with the help of a 
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catalyst. Although nanoparticle surfaces functionalized with amine, sulfhydryl, aldehyde and 
active hydrogen groups can be targeted, except for amine-functionalized nanoparticles, they are 
at risk of intercalation or cross linking.  
Click chemistry is the second method that can be used to achieve this conjugation. This 
technique was developed to make conjugation reactions between bioactive surfaces easier and 
less harsh to biomolecule ligands as they require mild reaction conditions and create 
biocompatible linkages (Hein et al., 2008). This method provides some unique advantages 
including the high specificity of azide and alkyne reactive groups for each other and 
uncreativeness towards most other functional groups. The bonds created using click chemistry 
are highly stable and extremely rigid which prevents cross interactions by helping to maintain the 
conformation of attached agents (Von Maltzahn et al., 2008; Sun et al., 2006). This method 
presents the ideal choice for applications where orientation and stability of the attached moiety 
are significantly important.  
Linker chemistry is the third method of creating covalent linkages. Its unique advantage lies in 
the control that it provides over the molecular orientation of bound agents which is a significant 
aspect of protecting targeting ligand functionality. The most common approach in linker 
chemistry involves a linker molecule that binds the amine group on the surface of a SPION with 
the sulfhydryl group of the binding agent or the cystine amino acid is targeted for reaction when 
the binding agent is a peptide or a protein. Linker chemistry is ideal for use in cases where a 
reaction with a complex biological molecule is required. This prevents over-labeling and 
reactions with multiple reactive sites (Veiseh et al., 2010).  
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In contrast to covalent linkages, physical interactions include any electrostatic, 
hydrophilic/hydrophobic and affinity interactions. Physical interactions are accompanied by 
rapid speed of binding, high efficiencies and do not require any intermediary modification steps. 
Attachment of insulin onto MNPs 
The idea of insulin‘s attachment onto the MNPs was explored further by Gupta et al (2003). This 
research group worked to couple insulin with superparamagnetic iron oxide nanoparticles of 
certain size and shape for targeting surface receptors on cells and thereby preventing endocytosis 
of the NPs. 1-Ethyl-3-(dimethylaminopropyl)-carbodiimide (EDCI) coupling method was used to 
covalently attach insulin onto the NP surface. This coupling method results in a fairly tight 
connection between insulin and the nanoparticles. This tight connection may affect the activity or 
functionality or conformation of the insulin molecule, as the tight connection can likely intervene 
the insulin. To reduce the likelihood of intervening the insulin from the nanoparticles, a soft 
chain made up of PEGDA was added between the MNP and the insulin molecule, which differs 
from the work of Gupta et al (2003).  
In sum, Section 2.5 provided a detailed analysis of the two potential capturing techniques, 
immunoprecipitation and the use of MNPs, and concluded that the latter approach was taken in 
this thesis study, thereby achieving part of Objective 1 of the thesis (see Chapter 1). 
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Chapter 3: Materials and Methods 
3.1 Materials 
3.1.1 Insulin 
Manufacturer Name:     Sigma-Aldrich 
Name in Manufacturer‘s Catalogue: I5500 – Insulin from bovine pancreas - ≥25 USP 
units/mg (HPLC), powder 
Empirical Formula:     C254H377N65O75S6 
Formula (Molecular) Weight:   5733.49 g/mol 
Properties: White, Powder form, Zinc cation traces of ≤1.0%, 
Storage temperature of -20
o
C. 
3.1.2 NH2
 
functionalized magnetic nanoparticles 
200 nm and 500 nm NH2 functionalized magnetic nanoparticles reacted with PEGDA (NH2-
MNP-PEGDA) were available to me through our research team member, Ruixue Yin. The 
following procedure describes her methodology (Yin et al., 2014):  
a. NH2 functionalized magnetic nanoparticles were obtained from Aladdin Reagent 
Co. Ltd Shanghai, China.  
b. 0.5 g PEGDA was added to 5 mL PBS (pH 7.4). 
c. 1 mL NH2 functionalized magnetic nanoparticles were added to the mixture.  
d. Solution was stirred at room temperature for 24 hours.  
e. After the reaction was over, the nanoparticles were concentrated by a magnet and 
washed for three times. 
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If insulin was attached directly onto the magnetic nanoparticles, there might have been a 
possibility of MNPs hindering insulin‘s structure or activity due to their close proximity. 
Addition of the PEGDA soft chain results in insulin‘s attachment further away from the MNPs 
and prevents insulin from facing any major effects of MNP‘s physiochemical properties.  
3.1.3 General Laboratory Chemicals Used 
 Hydrochloric acid (HCl) 37.5 % concentration 
o HCl was used to match the isoelectric point of the solution to that of the insulin 
used. Without using HCl, insulin would have precipitated in the PBS solution.  
 Phosphate buffered saline (PBS).  
3.1.4 Dialysis sacks 
Manufacturer Name:     Sigma-Aldrich 
Name in Manufacturer‘s Catalogue: D6191 – Dialysis sacks 
Pore size: 12000 Da MWCO 
Properties: Average flat width 25 mm, inflated diameter 
approximately 16 mm; pre-cut, open ended; dry; 
unwashed; approximate length of 30 cm (12 in.); 
will retain proteins with M.W. > 12000 Da. 
Dialysis was chosen as a method to get rid of the unbound insulin from the solution. Dialysis 
sacks combined with the tubing closures provided a gentle method to remove the unbound 
insulin. If the unbound insulin was left in the solution it would have resulted in convoluted 
results.   
 
46 
 
3.1.5 Dialysis tubing closures 
Manufacturer Name:     Sigma-Aldrich 
Name in Manufacturer‘s Catalogue: Z371092 – Dialysis tubing closures 
Properties: Blue; 50 mm; operating temperature range of 0 – 
90
o
C; made of Nylon 66.  
These tubing enclosures were a part of the dialysis kit. 
3.1.6 General laboratory equipment used 
Beakers, magnetic stirrers, magnetic stirring rods, weighing scale, pipettes, and plastic tubes. All 
of this equipment was used to successfully complete the experiment.  
3.2 Procedure for Synthesis 
Step 1: 1 mL 0.01 M HCl was added to 5 mg Insulin. 
Step 2: 4 mL PBS was added to the solution. 
Step 3: 1 mL 200 nm NH2-MNP-PEGDA were added to the solution. Note that NH2-
MNP-PEGDA underwent ultrasonic treatment for 5 minutes before addition to the 
solution. 
Step 4: The solution was stirred at room temperature for 24 hours.  
Step 5: The resulting solution was put into a dialysis tube for 24 hours to get rid of the 
unbound insulin.  
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3.2.1 Parallel Experiments 
Parallel experiments were run with 500 nm NH2-MNP-PEGDA. The only change to the 
synthesis procedure here was the replacement of the 200 nm NH2-MNP-PEGDA with 500 nm 
NH2-MNP-PEGDA. Each of these experiments was repeated five times and results were 
observed to be very similar. For simplicity purposes, the results from one experiment of each 
kind are presented below.  
Parallel experiments were also run in the absence of any nanoparticles at all. These experiments 
just involved insulin going through the synthesis procedure; the steps involving NH2-MNP-
PEGDA were taken out. The purpose of this parallel experiment was to gather information about 
insulin, so it can be compared to information gathered regarding the insulin – NH2-MNP-
PEGDA complex.  
Five different experiments were run in total and hence five different sets of spectra were 
generated and analyzed. Due to clarity, simplicity and conventional purposes, only spectra from 
the best sample set are presented below. A simple version of the methodology can be seen below 
in Figure 3-1. 
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3.3 Characterization  
3.3.1 Fluorescence spectrum 
Fluorescence measurements were carried out on a Pistar-180 CD spectrometer (Applied 
Photophysics Ltd., Leatherhead, UK) at room temperature using a 0.100 cm optical path length 
cuvette (Hellma, 106-QS). Protein solutions were scanned from 290 – 270 nm region in 1 nm 
steps. The baseline was measured using 1X PBS.  
Fluorescence spectrum was used to confirm the presence of insulin in our sample solutions. If the 
insulin-MNP attachment had failed, dialysis would have removed all of the insulin from the 
Figure 3-1: Representation of the MNP-Insulin complex synthesis. (a) magnetic nanoparticles 
and amino groups, (b) NH2 functionalized magnetic nanoparticles, (c) NH2 functionalized 
magnetic nanoparticles with PEGDA soft chain added, (d) final product: NH2 functionalized 
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solution. Fluorescence spectroscopy was used to confirm that insulin was present in the solution, 
which refers to Objective 1 of this thesis. Fluorescence spectroscopy provides a fast and simple 
method to measure the concentration of a particular substance in a sample solution based on its 
fluorescent properties. Fluorescence spectrometry can be used for a number of applications, 
which might require a range of analyses; either very complex or very simple. A complex analysis 
might involve using the fluorescence spectrum of an unknown compound and using the data to 
try to identify certain characteristics in it, which will point towards the identity of that 
compound. Fluorescence absorption spectrum helps us determine the identity of the unknown 
compound by giving information regarding which wavelengths were absorbed by the sample. 
Different compounds absorb different wavelengths, which gives them a unique identity and can 
be used to identify them. Fluorescence emission spectrum could also be used for the same 
purpose. However, the emission spectrum provides information, regarding which wavelengths 
are emitted by the unknown compound after absorbing the initial light. The wavelengths emitted 
are once again specific for certain compounds and can be used to identify them. An example of a 
relatively simple analysis is where the goal is to just determine the concentration of a compound 
that is already known to be present in the sample solution (Hooijschuur, n.d).  
3.3.2 Absorbance spectrum 
Absorbance measurements were carried out on a Pistar-180 CD spectrometer (Applied 
Photophysics Ltd., Leatherhead, UK) at room temperature using a 0.050 cm optical path length 
cuvette (Hellma, 106-QS). Protein solutions were scanned from 260 – 190 nm region in 1 nm 
steps. The baseline was measured using 1X PBS. 
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Absorbance spectroscopy is an analytical tool employed by chemists to measure the 
concentration of a certain substance in a sample solution, which can be used further to quantify 
the amount of the substance present. The absorbance spectrum shows how much light of a 
particular wavelength is absorbed by the sample solution. Although the data presented below can 
be used for the purpose of finding the exact concentration of insulin that was present in the 
solution by using the Beer-Lambert Law, this research did not have a need for that. Before 
moving onto more time consuming spectroscopies, we wanted to confirm the presence of insulin 
in our solution. 
Absorbance spectrum served a similar function to the fluorescence spectrum. Results from both 
spectroscopies were used to confirm the attachment of insulin onto the MNPs. The only reason 
an absorbance or fluorescence spectrum would indicate the presence of insulin in the solution is 
only if it was attached onto the MNPs otherwise it would have left the solution during dialysis, 
which refers to our Objective 1.  
3.3.3 CD spectrum 
CD measurements were carried out on a Pistar-180 CD spectrometer (Applied Photophysics Ltd., 
Leatherhead, UK) at room temperature using a 0.050 cm optical path length cuvette (Hellma, 106-
QS).  Protein solutions were scanned from 260-190 nm region in 0.5 nm steps at a scan rate of 5 nm 
min
-1
 and a bandwidth of 6 nm.  The baseline was measured using 1X PBS.  CD spectra displayed are 
an average of 4 spectra, and given in molar ellipticity (Θ) units. 
CD spectra are displayed as molar ellipticity ([θ]), which has units of deg cm2 dmol-1, and is 
calculated by the following equation:  
[ ]   
          
   
                                  (Equation 3.1) 
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where θobs is the measured ellipticity (deg), MW is the molecular weight of the protein (g mol
-
1
), c is the protein solution concentration (mg mL
-1
), b is the cuvette‘s pathlength (cm). The value 
of 100 originates from the conversion of molar concentration to dmol cm
-3
 concentration. 
Circular dichroism spectroscopy (CD) has a wide range of applications, however it is mainly 
used to investigate the secondary structure of proteins. It can very quickly provide information 
regarding the folding properties of proteins due to its ability to detect and quantify the proportion 
of alpha helices to beta sheets to random conformations. Protein CD is most widely used to 
determine whether or not the expressed protein, insulin in our case, is in its native conformation 
or if any mutations have occurred. This capability of CD is the reason that it is frequently used in 
the biopharmaceutical industry as a characterization tool. CD spectrums are used to study the 
effects of manufacturing processes, formulation compositions and conditions, storage conditions 
and delivery systems on protein conformation (Li et al., 2011). Different structural elements such 
as α-helices, β-sheets, etc., of proteins have characteristic CD spectra, which means if a protein 
structure is dominated by either one of the structural elements, its CD spectrum will be 
characteristic of that element. For instance, α-helical proteins display negative bands at a 
wavelength of 222 nm and 208 nm with a positive band at 195 nm. Proteins dominated by β-
sheets display negative bands at 218 nm and positive bands at 195 nm. Finally, proteins that are 
dominated by random structural elements display very low ellipticity above 210 nm (Greenfield, 
2007). 
If a certain protein was to undergo any mutation or conformational change, it would result in a 
shift in the placement of its positive or negative bands. For instance, if a protein whose structure 
is predominantly defined by β-sheets undergoes such conformational changes, its negative bands 
might not be found at 218 nm and its positive band might not be present at 195 nm, which as 
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mentioned above is the characteristic of proteins whose structure is dominated by β-sheets. As a 
CD spectrum of a protein provides information regarding its structure, especially the secondary 
structure, it was used to check if the insulin‘s conformation had undergone any changes during 
the synthesis processes. This would provide information regarding Objective 2 of this thesis. 
3.3.4 FTIR spectrum 
FTIR measurements were performed on a Biorad FTS-40 spectrometer using diffuse reflectance 
infrared Fourier transform (DRIFT) mode. Samples were mixed with spectroscopic grade KBr in 
an approximate 1:10 ratio.  FTIR spectra were an average of 256 spectra collected at room 
temperature in the 4000-400 cm
-1
 range using 4 cm
-1
 resolution. 
FTIR spectrum was also used because it would provide information regarding Objective 2. FTIR 
spectrums are used to study any conformational changes in protein structures. Fourier-transform 
infrared spectroscopy (FTIR) is used in a number of applications. Initially it was used for the 
analysis of organic compounds in order to gain information regarding their molecular structure, 
chemical bonding and molecular environment (Gerwert et al., 2010). FTIR‘s applications today 
range from its use in analysis of proteins, small molecules or molecular complexes all the way to 
use in analysis of cells or tissues. The analysis of proteins provides information regarding the 
protein conformation, folding and even the molecular details from protein active sites during 
enzyme reactions (Siebert et al., 2008). The data obtained through FTIR can be used to study 
conformational changes in proteins, hydrogen bonding interactions of cofactors and redox 
intermediates, proton transfer coupled to electron transfer, identification and properties of metal 
ligands, and even the role that water molecules play (Berthomier et al., 2009).  
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Although FTIR spectrum provides information regarding α-helices, it is particularly sensitive to 
the β-structures and any changes or mutations that they might present within a protein‘s 
structure. Therefore, it pairs well with circular dichroism, which as mentioned above is more 
sensitive towards α-helices. FTIR and CD spectroscopy are highly complementary towards each 
other, which is why both of them are used fairly commonly to study protein structures (Gerwert 
et al., 2010).  
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Chapter 4: Results and Discussion 
4.1 Fluorescence Spectroscopy 
Our purpose of using fluorescence spectroscopy was relatively simple. As presented in 
methodology, dialysis was used to get rid of the unbound insulin and if the attachment was not 
successful it would have gotten rid of all of the insulin. The fluorescence absorption spectrum 
was used to confirm that there was insulin present in our sample solution. The only reason any 
insulin would be left in the solution is if it was attached onto the MNPs. Therefore, the results in 
Figure 4-1 below also confirm the attachment of insulin onto the MNPs. Achievement of these 
Figure 4-1: Fluorescence spectra of insulin, 200 nm MNP + Insulin Complex and 500 nm 
MNP + Insulin Complex. 
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results refers to Objective 1.  
The reason that the insulin curve is much higher compared with the insulin-nanoparticle 
complexes is because insulin was at a much higher concentration compared to other samples. 
Insulin was at a higher concentration because the sample with just insulin did not go through a 
dialysis tube. There was not a feasible method present for us to calculate the concentration of 
insulin after dialysis. Therefore, I left the insulin concentration at the level it was before 
performing the dialysis. For the purposes of my study it was not necessary to have an exact 
concentration of insulin. One possible option to try and gauge the right amount of insulin was to 
dilute the insulin sample in a serial manner and once again run the different characterizations to 
see which one was the closest. Although I ran the serial dilutions I was not able to obtain a 
fluorescence spectrum for it due to the issues regarding laboratory equipment. However, the 
results in Figure 4-1 provide us with enough information regarding our questions. Insulin curve 
is higher and that is what we expected compared to the other two curves. A little difference 
between the 200 nm and 500 nm samples can also be attributed to slightly different 
concentrations of insulin being present in the solution. Despite the differences in the curves, we 
can safely say that insulin was present in each of our sample solutions and was ready to move 
onto next tests.  
4.2 Absorbance Spectroscopy 
The absorbance spectrum gives information regarding the signals given off by the aromatic rings 
in a certain protein. Different proteins absorb light at different wavelengths, which is why they 
project distinct absorbance spectra. The curves in Figure 4-2 show that there was a substance 
present in all three of the solutions and because the curves follow the same trajectory and have 
their peaks around the same wavelength it is safe to assume that all three contained the same 
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substance, insulin. The main reason for obtaining the absorbance spectra was to confirm the 
presence of insulin in our samples, which also confirms the attachment of insulin onto the MNPs. 
A dialysis procedure was used to get rid of any unbound insulin from the sample solutions. If the 
attachment of insulin and MNPs had not been successful, all of the insulin would have escaped 
the dialysis sack because insulin has a much smaller size compared to the pores in the dialysis 
sacks. The absorbance spectra would not have shown the presence of any substance. The dialysis 
sacks used for the experiment had a pore size of 12000 Da, which means they would have 
retained any proteins bigger in size than 12000 Da and any smaller proteins would have escaped 
the sack. Insulin used had a molecular weight of 5733.49 Da and therefore would have escaped 
the dialysis sacks unless it was bound to something bigger. According to the curves in Figure 4-2 
Figure 4-2: Absorbance spectra of insulin, 200 nm MNP + Insulin Complex and 500 nm MNP + 
Insulin Complex. 
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insulin was present in all three samples. The only reason that insulin would have been able to 
stay in the solution is if it had attached onto the MNPs, therefore the absorbance spectra below 
also confirm the attachment of insulin onto the MNPs. Achievement of these results further 
confirms the results of the fluorescence spectrum and refers to Objective 1.  
4.3 Circular Dichroism Spectroscopy 
Insulin has an alpha-helical secondary structure which means that it should have distinctively 
positive bands at 222 nm and 208 nm and a negative band near 195 nm. The results presented in 
Figure 4-3 show that the curves follow these parameters. All three curves presented below have 
their valleys very close to 222 nm and 208 nm, while the peak is towards 195 nm. Just as with 
the fluorescence spectrum results, these results could be analyzed in a much greater detail and a 
complex manner, however the purpose of this research was to confirm that no conformational 
changes took place after the attachment of insulin onto the MNPs. The fact that all of the curves 
have their peaks and valleys very close to each other means that no conformational changes took 
place in insulin‘s structure due to its attachment onto MNPs. Any shifts between these peaks and 
valleys would have indicated a conformational change in insulin. 
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Figure 4-3: CD spectra of insulin, 200 nm MNP + Insulin Complex and 500 nm MNP + Insulin 
Complex. 
Furthermore, the CD data obtained from experiments was analyzed using CDNN – Version 2.0, 
a specialized software designed to analyze data from CD spectra. Output from the software 
shows the CD spectrum and an estimate of the relative content of its secondary structural 
elements. Although the output presents estimates for different subsets of the full wavelength 
range, we opted to use the full wavelength range, 195 – 260 nm as it would provide the most 
comprehensive analysis. Also, the lowest wavelength prediction is proposed to be most reliable 
(jenalib.leibniz-fli.de, n.d). Table 1 below presents the output received from CDNN, net using 33 
basespectra (complex CD spectra). Ideally, the total sum of the secondary structural elements 
should be as close to 100% as possible. However, there is some room for error made by the 
program. As long as the total sum values presented do not deviate more than 5 – 10% from 
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100%, the data can be considered reliable. As Table 1 shows all three samples run for this 
research are well within the 5 – 10% error margin, the data presented below can be considered 
reliable. Moreover, the percentage represented for each structural element should also ideally be 
the same for all of the samples. However, just as with the total sum values the program allows 
some error margin, specifically if the data was obtained with in the 195 – 200 nm wavelength 
range and if the complex CD spectra were used, the error margin is 6.20%. More detailed error 
margins for different ranges and other spectra are presented in the appendix. The data in Table 1 
shows that percentage of each structural element for all three samples is within the 6.20% error 
margin. When the 200/500 nm MNPs + Insulin complexes are compared with Insulin samples 
according to the data below it can be safely said that insulin did not undergo any conformational 
changes as each structural element is still present within its percentage range when considering 
the error margin. Achievement of these results refers to Objective 2. 
Table 4-1: Secondary structural element percentages. 
Complex Insulin 200 nm MNPs + Insulin 500 nm MNPs + Insulin 
  195-260 nm 195-260 nm 195-260 nm 
Helix 11.60% 11.50% 13.20% 
Antiparallel 31.30% 34.00% 30.90% 
Parallel 5.50% 5.80% 5.90% 
Beta-Turn 19.70% 18.70% 18.90% 
Random Coil 33.50% 32.50% 32.50% 
Total Sum 101.70% 102.60% 101.50% 
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4.4 Fourier-transform Infrared Spectroscopy 
The peaks and valleys of the curves below represent data points that can be used for very 
complex analytical purposes. For instance the wavenumber (cm
-1
) range presented on the x-axis 
can be broken down into various regions which can be looked into with further detail to identify 
alpha-helices or beta-sheets and even postulate their percent composition. However, the purpose 
of this research was to see if insulin undergoes any conformational changes after its attachment 
onto the MNPs. This query can be answered by the fact that all of the peaks and valleys are 
found on locations that are very close to each other within all three curves. This so called 
‗superimposition‘ observed in the curves means that no structural or conformational changes 
took place in the insulin‘s structure after its attachment onto MNPs. If there were any shifts 
present within the peaks and valleys on the curves, especially within the 1510 – 1580 (Amide II 
band) and 1600 – 1700 (Amide I band) wavenumber ranges, which would have meant that 
somehow insulin‘s conformation had changed. Since no significant shifts are observed, we can 
safely say that insulin keeps its native conformation.  FTIR spectra are presented in Figure 4-4.  
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Further analysis of the amide I band is presented below. Amide I band is found in the range of 
1600 – 1700 cm-1. Amide I is observed to be the most intense absorption band in proteins and is 
directly related to the protein backbone conformation. It mainly shows the stretching vibrations 
of the carbon-oxygen double bond (C=꞊O) (70 – 85%) and about 10 – 20% of carbon-nitrogen 
(C---N) group vibrations (Jabs., n.d). Any significant changes within this band would represent a 
conformational change in the protein‘s backbone. As Figure 4-5 below shows the peak for all of 
the curves occurs at the 1658.98 wavenumber, this means that there was no shift observed within 
the samples. From this fact it can be concluded that insulin‘s conformation did not change after 
its binding onto the MNPs. Achievement of these results further confirms the results from the 
CD spectrum and refers to Objective 2.  
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0 500 1000 1500 2000 2500 3000 3500 4000 4500
In
te
n
si
ty
 
Wavenumber 
Insulin 200nm MNPs + Insulin Complex 500nm MNPs + Insulin Complex
Figure 4-4: FTIR spectra of insulin, 200 nm MNP + Insulin Complex and 500 nm MNP + 
Insulin Complex. 
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Figure 4-5: Amide I band of insulin, 200 nm MNP + Insulin Complex and 500 nm MNP + 
Insulin Complex.  
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Chapter 5: Conclusion and Future Work 
5.1 Conclusion 
After looking at the limitations of the current diabetes treatment/management strategies an 
interesting idea was developed, which would help improve the quality of life for diabetic patients 
and provide a possible solution to the problems associated with the insulin refill of the glucose-
responsive implantable devices. This idea can be summarized by the term ―Insulin Reuse‖; if the 
patients could use the insulin stored in the implantable devices for multiple cycles it would 
increase the availability of insulin and would subsequently decrease the requirement for 
multiple/frequent refills. This thesis looked at possible options to achieve this. The approach 
using magnetic nanoparticles was chosen as most viable. This research work was focused on the 
first step in the bigger picture idea of insulin reuse. Insulin was attached onto the NH2 
functionalized magnetic nanoparticles reacted with PEGDA and various characterization 
experiments were run to analyze the conformation of insulin. The purpose of these 
characterization experiments was to confirm that insulin does not undergo any conformational 
changes after its attachment onto MNPs.  
The results presented above show in detail that insulin‘s conformation was not affected by its 
attachment onto MNPs. Along with confirming the presence of insulin in the solutions, the 
fluorescence and absorbance spectra confirmed that second part of Objective 1 of this research 
was successfully achieved. The presence of insulin in the solution after dialysis could only have 
resulted if insulin was able to bind onto the MNPs. Detailed analysis of immunoprecipitation and 
the use of MNPs in literature review provides information regarding the first part of Objective 1. 
The CD and FTIR spectra used for further investigation provided details regarding the 
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conformation of insulin before and after its attachment onto the MNPs. The results from both of 
these spectra confirmed that Objective 2 of the research was successfully achieved as well. In 
achieving both of these objectives, the Research Question was also answered: Insulin can be 
attached onto the MNPs and its conformation will not be affected by the attachment.  
This study provided us with a new avenue of research that can be explored much further. As 
mentioned above this research has proven that insulin can be successfully attached onto the 
magnetic nanoparticles without any changes in its conformation. This information can be 
incorporated into various other ongoing studies on diabetes treatment and development of 
glucose-responsive implantable devices. The big picture idea discussed in this research has the 
potential to extend the bioavailability of insulin in these devices significantly. As suggested by 
the big picture idea, if insulin can be reused for multiple cycles, the maximum functional life of 
these devices can be increased. This provides a potential solution to a major limitation of such 
devices: maximum functional life of glucose-responsive implantable devices is too short.  
5.2 Limitations 
A. Our group only had access to two different sized nanoparticles (200 and 500 nm). The 
results obtained from these two sizes provide us with enough information to answer both of 
our objectives and can potentially be generalized over a wider range of sizes. It would have 
been desirable to have an even wider range of nanoparticles available to perform the 
experiments. 
B. This study was limited to in vitro testing. Although the in vitro testing is a stepping stone 
in a wider scheme of things, it limited the study to the conformational aspect and could not 
provide information regarding the functionality of insulin after the attachment.  
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5.3 Future Direction 
This research has shown that insulin‘s structure remains free of any conformational changes after 
its attachment onto MNPs. The next logical step would be to run some experiments that would 
test the biological activity of this insulin + MNP complex. These experiments could involve the 
usage of an even more diverse size range of nanoparticles. This would allow the research group 
to identify an ideal sized magnetic nanoparticle that should be used going further. If the insulin 
proves to be functional after those tests, the research could move onto the next steps in the bigger 
picture – insulin reuse. A more detailed literature review can be performed to shed light on the 
physiological requirements that the insulin-MNP complex would have to abide by in order to be 
used in vivo. Any new information that comes to light because of this literature review can be 
incorporated into the MNP and hence the insulin-MNP complex design. Besides the biological 
and physiological considerations, an analysis of design elements can be conducted with respect 
to the engineering impacts of such a complex. 
Also, an economic analysis can be performed to assess the economic feasibility of the work, 
resources and research that is going to be required in making the big picture a reality. As the 
insulin-MNP complex created is going to be used in a glucose-responsive implantable device, the 
requirements and needs of such a device are also worthy of consideration. The research group, 
going forward, can collaborate with another research group that is working to develop a glucose-
responsive implantable device and obtain important insights into the design elements. 
Potentially, an in vivo study/experiment can be performed in animals.  
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Appendix: CD Spectroscopy Error Margin 
  180-260 185-260 190-260 195-260 200-260 205-260 210-260 
NNET_13 4.32% 4.37% 4.35% 4.51% 4.63% 4.84% 4.91% 
NNET_23 4.87% 5.06% 5.03% 5.16% 5.38% 5.47% 5.44% 
NNET_33 3.98% 5.92% 5.57% 6.20% 6.45% 6.39% 6.60% 
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